Business
Tempus Announces Eight Abstracts Accepted for Presentation at the 2026 ASCO® Gastrointestinal Cancers Symposium
CHICAGO, January 08, 2026--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that eight abstracts have been accepted for presentation at the 2026 ASCO® Gastrointestinal Cancers Symposium. The meeting is being held on January 8–10 in San Francisco, California.
About this update from Ai, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/aa713bdf82fd152f2e34369b1da727bb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/1Tz6PQNFriIXCjZLCPXkug--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/aa713bdf82fd152f2e34369b1da727bb","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/OtvEzX4D0xz.XejDE_MfdA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/aa713bdf82fd152f2e34369b1da727bb","width":1024,"height":512}},"lazy":false},{"type":"text","content":"CHICAGO, January 08, 2026--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that eight abstracts have been accepted for presentation at the 2026 ASCO® Gastrointestinal Cancers Symposium. The meeting is being held on January 8–10 in San Francisco, California.","length":352,"tagName":"p"},{"type":"text","content":""The research Tempus is presenting at ASCO GI reflects our ongoing commitment to advancing progress in gastrointestinal cancers and demonstrates the power of utilizing our multimodal database to uncover novel insights in oncology," said Ezra Cohen, MD, Chief Medical Officer of Oncology at Tempus. "Across a variety of GI cancers, these studies show how our de-identified clinical and molecular data can be used to better characterize tumors, identify new biomarkers, and in some cases, find patient populations that may benefit from targeted therapies. We are proud to collaborate with all of the investigators who are helping to advance precision medicine."","length":679,"tagName":"p"},{"type":"text","content":"Tempus will highlight its latest scientific and clinical research findings via the following poster presentations:","length":114,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Genomic Profiling of Epithelial Neoplasms of the Appendix: Insights Across Histological Subtypes and Histological Grades","length":120,"tagName":"p","attribs":{}},{"type":"list","items":[{"val":[{"type":"text","content":"Date/Time: Thursday, January 8, 11:30 a.m.–1:00 p.m. and 6:0...